For simultaneously mobilizing the adaptive and innate immune system against cancer, we fused interleukin (IL)-2 and IL-12 to generate a dual cytokine moiety that is targeted to neoplastic lesions by an antibody-binding domain. This approach elicits a broader attack of the immune system against cancer than the use of each cytokine alone.
Keywords: Hodgkin's lymphoma; IL-12; IL-2; NK cell; T cell; T helper cell polarization; antibody-cytokine fusion protein; immune therapy.